144550-76-5

Basic information

• Product Name: Methyl2-Amino-4-Iodobenzoate
• Synonyms: Methyl2-Amino-4-Iodobenzoate
• CAS NO: 144550-76-5
• Molecular Formula: C₈H₈INO₂
• Molecular Weight: 277.05909
• Mol File: 144550-76-5.mol

Chemical Properties

• Melting Point: 71-73 °C
• Boiling Point: 337.7±32.0 °C(Predicted)
• Appearance: /
• Density: 1.826±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.39±0.10(Predicted)
• CAS DataBase Reference: Methyl2-Amino-4-Iodobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl2-Amino-4-Iodobenzoate(144550-76-5)
• EPA Substance Registry System: Methyl2-Amino-4-Iodobenzoate(144550-76-5)

Safety Data

• Hazardous Substances Data: 144550-76-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl2-Amino-4-Iodobenzoate is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure, which includes an amino group, an iodine atom, and a methyl ester, makes it a valuable building block in the development of new drugs and medications.
Used in Chemical Synthesis:
Methyl2-Amino-4-Iodobenzoate is used as a chemical intermediate in the synthesis of other organic compounds. Its functional groups can be utilized in various chemical reactions, allowing for the creation of a wide range of products in the chemical industry.
Note: Since the provided materials do not specify the exact applications of Methyl2-Amino-4-Iodobenzoate, the uses listed above are based on the general understanding of its role as a chemical intermediate. Further research and information would be required to identify specific applications in different industries.

Upstream product

• 791098-21-0 methyl 2-nitro-4-iodobenzoate 
• 117324-10-4 2-acetylamino-4-iodobenzoic acid 
• 115081-94-2 7-iodo-1H-benz[d][1,3]oxazine-2,4-dione 
• 67-56-1 methanol 
• 186581-53-3 diazomethane 
• 20776-54-9 2-amino-4-iodobenzoic acid 

Downstream Products

• 1005029-90-2 2-(5'-iodo-2'-methoxycarbonylphenylamino)benzoic acid 
• 144550-77-6 (2-methoxycarbonyl-5-iodobenzene)disulfide 
• 123102-32-9 methyl 2-amino-6-ethyl benzoate 
• 1228960-81-3 methyl 4-iodo-2-[(4-methoxy-4-oxobutanoyl)amino]benzoate 
• 1246775-81-4 methyl 2-(benzylamino)-4-iodobenzoate 
• 144550-36-7 methyl 4-iodo-2-[[[[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)amino] carbonyl]amino]sulfonyl]benzoate sodium salt 
• 144550-06-1 methyl 4-iodo-2-[[[[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)amino]carbonyl]amino]sulfonyl]benzoate 
• 144550-79-8 2-methoxycarbonyl-5-iodobenzenesulfonamide 
• 884197-15-3 9-iodo-2-(3,4-dimethoxyphenylamino)-5H-benzo[b]pyrimido[4,5-d]azepin-6(7H)-one 

Relevant articles and documents

PROCESS FOR PREPARING A NOVEL CRYSTALLINE FORM OF IODOSULFURON-METHYL-SODIUM AND USE OF THE SAME

A crystalline form of iodosulfuron-methyl-sodium of formula (I), the crystal preparation process, the analyses of the crystal through various analytical methods and using the crystal to prepare stable agrochemical formulation. The invention also describes the use of various solvents towards the crystalline form preparation conditions.

Synthesis of substituted indole from 2-aminobenzaldehyde through [1,2]-aryl shift

A mild, efficient, and simple method for the synthesis of 3-ethoxycarbonylindoles has been developed. Addition of ethyl diazoacetate (EDA) to 2-aminobenzaldehydes cleanly affords the indole core. As opposed to other common approaches for the synthesis of indole, this method displays both excellent functional group tolerance and perfect regiochemical control. This allowed the synthesis of a variety of useful indole building blocks from 2-aminobenzaldehydes derived from readily available anthranilic acids.

5, 7-DIHYDRO- 6H-PYRIMIDO [ 5, 4-D] [ 1 ] BENZAZEPIN-6-THIONES AS PLK INHIBITORS

This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, and R6 are as described in the specification. The compounds are inhibitors of PLK and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma

Various iodo-acridone and acridine carboxamides have been prepared and evaluated as agents for targeted radionuclide and/or chemotherapy for melanoma, due to their structural similarity to benzamides which are known to possess specific affinity for melanin. Three of these carboxamides selected for their in vitro cytotoxic properties were radioiodinated with [125I]NaI at high specific activity. Biodistribution studies carried out in B16F0 murine melanoma tumour-bearing mice highlighted that acridone 8f and acridine 9d, presented high, long-lasting tumour concentrations together with an in vivo kinetic profile favourable to application in targeted radionuclide therapy.

SULFONAMIDE COMPOUNDS

Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases.

Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists

A high throughput screening approach to the identification of selective cholecystokinin-2 receptor (CCK-2R) ligands resulted in the discovery of a novel series of antagonists, represented by 1-[2-[(2,1,3-benzothiadiazol-4- ylsulfonyl)amino]-5-chlorobenzoy

LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS

The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Quinoxaline compounds

Certain amidophenyl-sulfonylamino-quinoxaline compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.

Benzo[1,2,5]thiadiazole compounds

Certain amidophenyl-sulfanylamino-benzo[1,2,5]thiadiazole compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.

Pyridazinedione compounds useful in treating neurological disorders

The present invention relates to pyridazino[4,5-b]quinolines, and pharmaceutically useful salts thereof, which are excitatory amino acid antagonists and which are useful when such antagonism is desired such as in the treatment of neurological disorders. The invention further provides pharmaceutical compositions containing pyridazino[4,5-b]quinolines as active ingredient, and methods for the treatment of neurological disorders.